Janux Therapeutics develops immunotherapy drugs that direct the immune system's T cells to attack tumors and autoimmune disease. It last closed at $10.71 on Nov 17, down 1.92% on the day. The average 12-month price target from 4 analysts is $26.25 (+145.1% from the last close), with a high of $40.00 and a low of $15.00. Analyst consensus is Buy, based on the latest ratings from 4 firms (3 buy, 0 hold, 1 sell). In the past 30 days there were 1 dark pool print totaling $457K, the largest $457K.
Each firm's latest rating on JANX in the past 90 days
Average 12-month target
$26.25
▲ 145.1% upside
Based on 4 analysts who set a price target on JANX in the past 90 days. The average target is $26.25, with a high of $40.00 and a low of $15.00, compared with the last close of $10.71.
Highest target$40.00
Average target$26.25
Lowest target$15.00
Latest rating changes
Truist SecuritiesTarget raised
Nov 6Buy$26 → $27
WedbushMaintained
Nov 6Buy$40
BarclaysTarget raised
Nov 6Sell$14 → $15
Wolfe ResearchUpgrade
Aug 24Buy$23
GuggenheimMaintained
Aug 7Buy$55
Date
Firm
Action
Rating
Price target
Nov 6
Truist Securities
Target raised
Buy
$26 → $27
Nov 6
Wedbush
Maintained
Buy
$40
Nov 6
Barclays
Target raised
Sell
$14 → $15
Aug 24
Wolfe Research
Upgrade
Buy
$23
Aug 7
Guggenheim
Maintained
Buy
$55
Loading…
Technical Analysis
JANX · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 43% below its 20 day and 53% below its 50 day average. It is 43% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the 52 week low at $10.53, and the nearest resistance the Pivot at $10.72.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 10.1%/day
Key levels
$35.3452 week high+230.0%
$16.55100 day average+54.5%
$16.4350 day average+53.4%
$15.3420 day average+43.2%
$15.33200 day average+43.1%
$14.03Swing high (Jun 10)+31.0%
$10.91Pivot R1+1.9%
$10.72Pivot+0.1%
$10.71Last close
$10.5352 week low−1.7%
$10.52Pivot S1−1.8%
Indicators
RSI (14)
27.12
Oversold below 30
Oversold
MACD
-1.64
Below its signal line
Bearish
Stochastic
2.5
Near the bottom of its range
Oversold
ADX (14)
29.3
Trending down
Williams %R
-97.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-128.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−39.9%
Change over 10 sessions
Bearish
ATR (14)
$1.08
Typical daily range, 10.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNear oversold
VolatilityHigh, 19.7%/day
Key levels
$35.3452 week high+230.0%
$16.55100 day average+54.5%
$16.4350 day average+53.4%
$15.3420 day average+43.2%
$15.33200 day average+43.1%
$14.03Swing high (Jun 10)+31.0%
$10.91Pivot R1+1.9%
$10.72Pivot+0.1%
$10.71Last close
$10.5352 week low−1.7%
$10.52Pivot S1−1.8%
Indicators
RSI (14)
33.73
Weak, oversold below 30
Neutral
MACD
-0.55
Below its signal line
Bearish
Stochastic
18.3
Near the bottom of its range
Oversold
ADX (14)
20.1
Weak trend
Williams %R
-98.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-305.7
Oversold below −100, overbought above 100
Oversold
Rate of change
−37.4%
Change over 10 sessions
Bearish
ATR (14)
$2.11
Typical daily range, 19.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for JANX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how JANX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow JANX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How JANX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JANX is in one of them and how their past JANX trades turned out.
Janux Therapeutics is a biopharmaceutical company based in San Diego, California. It develops immunotherapy drugs that direct the body's T cells to attack tumors, and it is also developing treatments for autoimmune diseases. Its lead candidates are in clinical trials for prostate cancer and other solid tumors. The company's drug candidates are aimed at cancer patients and people living with autoimmune conditions.